Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Details (Tables)

3 Months Ended

Mar. 31, 2022

	March 31,		December 31,
	2022		2021
Prepaid expenses and other current assets
Prepaid insurance	$	455,592	$	769,416
Prepaid research and development costs		138,810		-
Prepaid other		79,063		-
Deferred offering costs		179,592		55,718
Total prepaid expenses and other current assets	$	853,057	$	825,134

Accrued and other current liabilities
Accrued research and development costs	$	245,174	$	235,384
Accrued compensation and benefits		155,272		766,207
Accrued legal fees		73,195		-
Accrued board compensation		55,625		-
Total accrued and other current liabilities	$	529,266	$	1,001,591